Plasma Proteomics Enable Differentiation of Lung Adenocarcinoma from Chronic Obstructive Pulmonary Disease (COPD)

Int J Mol Sci. 2022 Sep 24;23(19):11242. doi: 10.3390/ijms231911242.

Abstract

Chronic obstructive pulmonary disease (COPD) is a major risk factor for the development of lung adenocarcinoma (AC). AC often develops on underlying COPD; thus, the differentiation of both entities by biomarker is challenging. Although survival of AC patients strongly depends on early diagnosis, a biomarker panel for AC detection and differentiation from COPD is still missing. Plasma samples from 176 patients with AC with or without underlying COPD, COPD patients, and hospital controls were analyzed using mass-spectrometry-based proteomics. We performed univariate statistics and additionally evaluated machine learning algorithms regarding the differentiation of AC vs. COPD and AC with COPD vs. COPD. Univariate statistics revealed significantly regulated proteins that were significantly regulated between the patient groups. Furthermore, random forest classification yielded the best performance for differentiation of AC vs. COPD (area under the curve (AUC) 0.935) and AC with COPD vs. COPD (AUC 0.916). The most influential proteins were identified by permutation feature importance and compared to those identified by univariate testing. We demonstrate the great potential of machine learning for differentiation of highly similar disease entities and present a panel of biomarker candidates that should be considered for the development of a future biomarker panel.

Keywords: Ig kappa light chain; SAA1; SERPINA3; artificial intelligence; lung cancer; machine learning; plasma proteomics; random forest.

MeSH terms

  • Adenocarcinoma of Lung*
  • Biomarkers
  • Humans
  • Lung Neoplasms* / diagnosis
  • Lung Neoplasms* / pathology
  • Proteomics
  • Pulmonary Disease, Chronic Obstructive* / pathology

Substances

  • Biomarkers